Zenosense, Inc. (ZENO) Moves Forward with Manufacturing Pre- Zenosense, Inc. (ZENO) Moves Forward with Manufacturing Pre-Market Lung Cancer Detection Device
Zenosense is a company on a mission. The emerging healthcare technology company has undertaken the challenge of developing functioning yet cost-effective medical devices that will detect, early on, deadly bacteria and certain cancers in a patient’s exhaled breath.
The company currently has two devices under development:
• a device intended to detect lung cancer
• a device intended to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA)
The process of developing the lung cancer detection device has been interesting lately. This past November, Zenosense revealed plans to manufacture a pre-market prototype device that will eventually be evaluated during a lung cancer detection trial in a clinical setting.
Zenon Biosystem, Zenosense’s contracted development partner and a member company of the Sgenia Group, has undertaken the task of manufacturing the prototype. In preparation for the expected lung cancer detection trial and in accordance with the protocol design for the trial, Zenon will manufacture two pre-commercial devices of identical design to ensure that trial results can be replicated.
The device will be designed using an Electronic Nose technology platform. It will incorporate components capable of filtering out Volatile Organic Compounds (VOCs) that are not of interest in order to improve the detection of specific VOC biomarkers found in exhaled breath and linked to the incidence of lung cancer. In keeping with its mission, Zenosense means to use components of a relatively low cost to create this product cost-effectively.
Zenon is hard at work establishing the necessary collaborations needed to carry out the planned lung cancer detection trial, and Zenosense is eagerly anticipating the testing of the prototype in the trial. Zenosense believes a cost-effective, breath-analyzing lung cancer detector that is proven to meet or, better yet, exceed the accuracy of low-dose Computed Tomography (CT) scanning will generate wide appeal and, subsequently, substantial demand.
For more information, visit the company’s website at www.zenosense.net
Please see disclaimer on the QualityStocks website: https://Disclaimer.QualityStocks.com